Académique Documents
Professionnel Documents
Culture Documents
ScientificAmerican.com
Ta c k l i n g M a j o r K i l l e r s : CANCER exclusive online issue no. 17
More than 1.36 million Americans will be diagnosed with cancer in 2004, and 563,700 will succumb to the disease, according to estimates
from the American Cancer Society. Accounting for one in four mortalities, cancer is second only to heart disease when it comes to cause of
death. These grim statistics notwithstanding, researchers have made great strides in understanding--and combating--the scourge. Thanks
to their efforts, a number of new cancer-fighting tactics are on the horizon.
In this exclusive online issue, comprised of articles published over the past five years, leading scientists and journalists explain recent
advances in cancer research. Learn how cells become malignant; how viruses, dendritic cells and light-sensitive pigments are finding work
as anti-cancer agents; and how researchers might one day be able to manipulate the formation of new blood vessels to treat the disease.
Other reports explain why hormone-replacement therapy may not be such a bad idea--and why alternative medicine is. In addition, two arti-
cles sketch Judah Folkman, who discovered that two natural compounds dramatically shrink tumors by cutting off their blood supply, and
Peter Duesberg, who has claimed that the scientific establishment has an incorrect theory of how cancer arises.The Editors
TABLE OF CONTENTS
2 Untangling the Roots of Cancer
BY W. WAYT GIBBS; THE SCIENCE OF STAYING YOUNG
Recent evidence challenges long-held theories of how cells turn malignant--and suggests new ways to stop tumors before they
spread
33 Tumor-Busting Viruses
BY DIRK M. NETTELBECK AND DAVID T. CURIEL; OCTOBER 2003
A new technique called virotherapy harnesses viruses, those banes of humankind, to stop another scourge - cancer
41 Hormone Hysteria
BY DENNIS WATKINS; OCTOBER 2003
Hormone replacement therapy may not be so bad
CAREFULLY CHOREOGRAPHED
dance of chromosomes occurs
during cell division. Missteps that
mangle chromosomes or that send
the wrong number to each daughter
cell may be critical events early
in the development of cancer,
according to new theories.
By W. Wayt Gibbs
that science was homing in on a final answer: cancer is the Pieces of chromosomes are frequently scrambled, trun-
result of cumulative mutations that alter specific locations cated or fused together. Chemical additions to the DNA,
in a cells DNA and thus change the particular proteins en- or to the histone proteins around which it coils, somehow
coded by cancer-related genes at those spots. The muta- silence important genes but in a reversible process quite
tions affect two kinds of cancer genes. The first are called different from mutation.
tumor suppressors. They normally restrain cells ability to The accumulating evidence has spawned at least three
divide, and mutations permanently disable the genes. The hypotheses that compete with the standard dogma to ex-
second variety, known as oncogenes, stimulate growth plain what changes come first and which aberrations mat-
in other words, cell division. Mutations lock oncogenes ter most in the transformation of a cell and its descendants
5. EFFECTIVE IMMORTALITY
Healthy cells can divide no more than 70 times. Malignant cells need more than that to make tumors. So
they work around systemssuch as the telomeres at the end of chromosomesthat enforce the
reproductive limit.
percent of colorectal, and 34 percent of deletes or disrupts a tumor suppressor another burst of growth.
breast cancers. By then the prognosis is gene RB, p53 and APC are among Cells normally have two copies of
frequently grim. the best known thereby suppressing every chromosome one from the moth-
proteins that normally ensure the in- er, the other from the father and thus
The Order of Disorder tegrity of the genome and cell division. two copies, or alleles, of every gene. (In
DOCTORS COULD CATCH incipient Alternatively, a mutation may increase males, the single X and Y chromosomes
tumors sooner if scientists could trace the the activity of an oncogene such as are notable exceptions.) A mutation to
steps that cells take down the road to BRAF, c-fos or c-erbb3whose proteins just one allele is enough to activate an
cancer after the initial assault to their then stimulate the cell to reproduce. oncogene permanently. But it takes two
DNA by a carcinogen or some random Changes to cancer genes endow the hits to knock out both alleles of a tumor
biochemical mishap. Researchers broad- cell with one or more superpowers, al- suppressor gene. Four to 10 mutations in
ly agree on the traits of the diseased cells lowing it to outbreed its neighbors. The the right genes can transform any cell. Or
that emerge from the journey. It is the cell passes abnormalities in its DNA se- so the theory goes.
propelling force and the order of each quence on to its descendants, which be- The mutant-gene paradigm gained
milestone that are under active debate. come a kind of clone army that grows to almost universal acceptance because it
The dominant paradigm has been the limits of its capacity. Eventually an- explained very well what scientists saw
that tumors grow in spurts of mutation other random mutation to a cancer gene in their experiments on genetically engi-
and expansion. Genetic damage to a cell knocks down another obstacle, initiating neered mice and human cell cultures.
1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
rapidly, lamented Weinberg and Hahn and repair machinerymust dramatical- chromosomal instability can occur ear-
in their 2002 review. As a consequence, ly accelerate the mutation rate, Loeb ar- ly on. The genetic flux then combines
they added, it remains possible that each gues. I think that is probably right, forces with natural selection to produce
tumor is unique in the pattern of its ge- Hahn concurs. Otherwise, he says, cells a benign growth that may later be con-
netic disarray. wouldnt accumulate a sufficient number verted to an invasive malignancy and
Hahn reflected on this possibility in of mutations to form a tumor. life-threatening metastases.
his Boston office in January 2003. Along Loeb believes that early during the In their hypothesis, there are several
with Weinberg, he has pioneered the genesis of cancer there are enormous master genes whose function is critical
construction of artificial tumors using numbers of random mutations 10,000 for a cell to reproduce correctly. If as few
mutant cancer genes. But he acknowl- to 100,000 per cell. Evidence for the as one of these genes is disabled, either by
edged that they cannot be the whole sto- theory is still slim, he acknowledges. mutation or epigenetically, the cell stum-
ry. The question is which comes first, Counting random mutations is hard; sci- bles each time it attempts cell division,
he said. Mutations or aneuploidy? entists must compare the genomes of in- muddling some of the chromosomes into
There are at least three competing dividual cells letter by letter. Advances an aneuploid state. One result is to in-
answers. Let us call them the modified in biotechnology have only recently crease 100,000-fold the rate at which
dogma, the early instability theory and made that feasible. cells randomly lose one of the two alleles
the all-aneuploidy theory. Encouraging- The modified dogma thus adds a of their genes. For a tumor suppressor
ly, the theories seem to be converging as prologue to the accepted life history of gene, a lost allele may effectively put the
they bend to accommodate new experi- cancer. But the most important factors gene out of commission, either because
mental results. are still mutations to genes that serve to the remaining copy is already mutated or
The modified form of the standard increase the reproductive success of cells. because of the haploinsufficiency effect.
dogma revives an idea proposed in 1974 Mangled and ever changing chromo- Lengauer and Vogelstein still assume
by Lawrence A. Loeb, now at the Uni- somes are but fortuitous by-products. that some cancer genes must be altered
versity of Washington. He and others before a malignancy can erupt.
have estimated that random mutation Unstable from the Outset In December 2002, together with
will affect just one gene in any given cell CRISTOPH LENGAUER and Vogel- Martin A. Nowak and Natalia L. Ko-
over a lifetime. Something a carcino- stein of Johns Hopkins, both well- marova of the Institute for Advanced
gen, reactive oxidants, or perhaps a mal- known colon cancer specialists, have Study in Princeton, N.J., Lengauer and
function in the cells DNA duplication proposed an alternative theory in which Vogelstein published a mathematical
7 SCIENTIFIC AMERICAN EXCLUSIVE ONLINE ISSUE OCTOBER 2004
1 Something silences one or more The dosage of genes in the cell changes as
master genes that are critical chromosome pieces are added or deleted
for coordinated cell division
EARLY INSTABILITY
4 Eventually one or more cells acquire a mix of aberrant co-workers may have uncovered a clue in
chromosomes that conveys one or more of the superpowers a March 2003 study of 116 premalignant
of cancer. The cells multiply into a precancerous tumor tumors caught before they had invaded
neighboring tissues of the cervix, prostate
9 SCIENTIFIC AMERICAN EXCLUSIVE ONLINE ISSUE OCTOBER 2004
COPYRIGHT 2004 SCIENTIFIC AMERICAN, INC.
and breast. Thirty to 72 percent of the Thomas Ried, chief of cancer ge- delay the tumors growth. You are not
growths contained defective centrosomes, nomics at the National Cancer Institute, going to cure it.
structures that appear during cell division has obtained supporting evidence in hu- For the elderly who, after all, are
to help separate the duplicated chromo- mans with cervical and colorectal can- the main victims of cancer a sufficient
somes from the originals. Most of those cers. Unequivocally, there are recurrent delay may be as good as a cure. And even
cells were aneuploid. Scientists are still patterns of genomic imbalances, Ried better than slowing the growth of a tu-
working out the genes that control cen- avers. Every single case of [nonheredi- mor would be to delay its formation in
trosome formation and function; any of tary] colorectal cancer, for example, has the first place. If Lengauer and other ad-
them might be a master gene. gains of chromosomes 7, 8, 13 or 20 or herents of the early instability theory suc-
a loss of 18. In cervical cancer, aneu- ceed in identifying master genes, then it
Aneuploidy All the Way Down ploidy of chromosome 3 happens very should also be possible to make drugs
O N T H E O T H E R H A N D , maybe cells early, and those cells seem to have a se- that protect or restore their function.
can become malignant even before any lective advantage. Ried finds the aver- Lengauer says his group has already li-
master genes, oncogenes or tumor sup- age number of abnormal chromosomes censed cell lines to the pharmaceutical in-
pressor genes are mutated. Peter H. increasing gradually from 0.2 in a nor- dustry to use in drug screening.
Duesberg and Ruhong Li of the Univer- mal cell to 12 in the cells of metastatic Screening of a different kind may be
sity of California at Berkeley have put colon tumors. the best approach if the all-aneuploidy
forth a third theory: nearly all cancer So I think Duesberg is right that theory is correct. There is no known
cells are aneuploid because they start aneuploidy can be the first genetic aber- means of selectively killing cells with ab-
that way. Lots of things can interfere ration in cancer cells, Ried says. But normal chromosomes. But a biopsy that
with a dividing cell so that one of its he also argues that no gene mutations turns up a surfeit of aneuploid cells
daughter cells is cheated of its normal are required. This is simply not true. might warrant careful monitoring or
complement of 46 chromosomes and even preventive surgery in certain cases.
the other daughter is endowed with a Stopping Cancer at Its Roots And Duesberg suggests that foods, drugs
bonus. Asbestos fibers, Duesberg notes, N E I T H E R T H E standard dogma nor and chemicals should be tested to iden-
can physically disrupt the process. any of the new theories can explain the tify compounds that cause aneuploidy.
Most aneuploid cells are stillborn or 100-odd diseases we call cancer as varia- One day science will produce a de-
growth-retarded. But in the rare sur- tions of a single principle. And all the the- finitive answer to the question of what
vivor, he suggests, the dosage of thou- ories will need to be expanded to incor- causes cancer. It will probably be a very
sands of genes is altered. That corrupts porate the role of epigenetic phenomena. complicated answer, and it may force us
teams of enzymes that synthesize and It is important to determine which of to shift our hope from drugs that cure the
maintain DNA. Breaks appear in the the ideas is more correct than the others, disease to medicines that prevent it. Even
double helix, destabilizing the genome because they each make different pre- without a clear understanding of why,
further. The more aneuploid the cell is, dictions about the kinds of therapy that doctors have discovered that a daily baby
the more unstable it is, and the more like- will succeed. In the standard view, tu- aspirin seems to prevent colon adenomas
ly it will produce new combinations of mors are in effect addicted to the pro- in some adults. The effect is small. But it
chromosomes that will allow it to grow teins produced by oncogenes and are is a step from chemotherapy toward a
anywhere, Duesberg explains. poisoned by tumor suppressor proteins. better alternative: chemoprevention.
Unlike the three other theories, the Medicines should therefore be designed
all-aneuploidy hypothesis predicts that to break the addiction or supply the poi- W. Wayt Gibbs is senior writer for
the emergence and progress of a tumor son. Indeed, this strategy is exploited by Scientific American.
are more closely connected to the as- some newer drugs, such as Gleevec (for
MORE TO E XPLORE
sortment of chromosomes in its cells rare forms of leukemia and stomach
Chromosome Segregation and Cancer:
than to the mutations in the genes on cancer) and Herceptin (for one variety of Cutting through the Mystery. Prasad V.
those chromosomes. Some observations advanced breast cancer). Jallepalli and Cristoph Lengauer in Nature
do seem to corroborate the idea. But all existing therapies fail in some Reviews Cancer, Vol. 1, No. 2, pages 109117;
In May 2003, for instance, Duesberg patients because their tumors evolve into November 2001.
and scientists at the University of Hei- a resistant strain. Loeb fears that there Rules for Making Human Tumor Cells. William
delberg reported on experiments with may be no easy way around that prob- C. Hahn and Robert A. Weinberg in New
England Journal of Medicine, Vol. 347, No. 20,
normal and aneuploid hamster embryos. lem. If I am right, then within any giv- pages 15931603; November 14, 2002.
The more the cells deviated from the cor- en tumor, which contains roughly 100 Multiple Mutations and Cancer. Lawrence A.
rect number of chromosomes, the faster million cells, there will be cells with ran- Loeb, Keith R. Loeb and Jon P. Anderson
aberrations accumulated in their chro- dom mutations that protect them from in Proceedings of the National Academy
mosomes. Genomic instability rose ex- any treatment you can conceive, Loeb of Sciences USA, Vol. 100, No. 3,
pages 776781; February 4, 2003.
ponentially with greater aneuploidy. says. So the best you can hope for is to
VESSELS
of DEATH
Angiogenesisthe formation of new blood vessels
might one day be manipulated to treat disorders
from cancer to heart disease. First-generation drugs
are now in the final phase of human testing
The
LONG
Dendritic cells
catch invaders and tell
ARM
the immune system when
and how to respond. Vaccines
of the
depend on them, and scientists are
even employing the cells to stir up
immunity against cancer
By Jacques Banchereau
into pieces called antigens and display the antigens on their surfaces. from mice.
Antigen-bearing dendritic cells travel to lymph nodes or the spleen, where they In 1994 researchers led by Antonio
interact with other cells of the immune system including B cells, which make Lanzavecchia, now at the Institute for Re-
antibodies, and killer T cells, which attack microbes and infected cells. search in Biomedicine in Bellinzona,
Cancer vaccines composed of dendritic cells bearing tumor antigens are now in Switzerland, and Gerold Schuler, now at
clinical trials involving humans. Scientists are also hoping to turn off the the University of Erlangen-Nuremberg in
activity of dendritic cells to combat autoimmune diseases such as lupus. Germany, found a way to grow the cells
from white blood cells called monocytes.
Scientists now know that monocytes can pitchfork-shaped molecules termed the case it ever returns.
be prompted to become either dendritic major histocompatibility complex (MHC) Whether the body responds with an-
cells, which turn the immune system on to display the antigens on their surfaces. tibodies or killer cells seems to be deter-
and off, or macrophages, cells that crawl The antigens fit between the tines of the mined in part by which subset of dendrit-
through the body scavenging dead cells MHC, which comes in two types, class I ic cell conveys the message and which of
and microbes. and class II. The two types vary in shape two types of immune-stimulating sub-
The ability to culture dendritic cells and in how they acquire their antigen car- stances, called cytokines, they prompt the
offered scientists the opportunity to in- go while inside cells. helper T cells to make. In the case of par-
vestigate them in depth for the first time. Dendritic cells are very efficient at cap- asites or some bacterial invaders, type 2
Some of the initial discoveries expanded turing and presenting antigens: they can cytokines are best because they arm the
the tenuous understanding of how den- pick up antigens that occur in only immune system with antibodies; type 1
dritic cells function. minute concentrations. As they process cytokines are better at mustering killer
There are several subsets of dendritic antigens for presentation, they travel to cells to attack cells infected by other kinds
cells, which arise from precursors that the spleen through the blood or to lymph of bacteria or by viruses.
circulate in the blood and then take up nodes through a clear fluid known as If a dendritic cell prompts the wrong
residence in immature form in the skin, lymph. Once at their destinations, the type of cytokine, the body can mount the
mucous membranes, and organs such as cells complete their maturation and pre- wrong offense. Generating the appropri-
the lungs and spleen. Immature dendrit- sent their antigen-laden MHC molecules ate kind of immune response can be a
ic cells are endowed with a wealth of to naive helper T cells, those that have matter of life or death: when exposed to
mechanisms for capturing invading mi- never encountered antigens before. Den- the bacterium that causes leprosy, people
crobes: they reel in invaders using suction dritic cells are the only cells that can edu- who mount a type 1 response develop a
cuplike receptors on their surfaces, they cate naive helper T cells to recognize an mild, tuberculoid form of the disease,
take microscopic sips of the fluid sur- antigen as foreign or dangerous. This whereas those who have a type 2 response
rounding them, and they suck in viruses unique ability appears to derive from co- can end up with the potentially fatal lep-
or bacteria by engulfing them in sacks stimulatory molecules on their surfaces romatous form.
known as vacuoles. Yong-Jun Liu, a for- that can bind to corresponding receptors
mer colleague of mine from Schering- on the T cells. Cancer Killers
Plough who is now at DNAX Research Once educated, the helper T cells go A C T I V A T I N G N A I V E helper T cells is
Institute in Palo Alto, Calif., has found on to prompt so-called B cells to produce the basis of vaccines for everything from
that some immature dendritic cells can antibodies that bind to and inactivate the pneumonia to tetanus to influenza. Sci-
also zap viruses immediately by secreting antigen. The dendritic cells and helper entists are now turning the new knowl-
a substance called interferon-alpha. cells also activate killer T cells, which can edge of the role that dendritic cells play in
JACQUES BANCHEREAU
Once they devour foreign objects, the destroy cells infected by microbes. Some immunity against microbes and their tox-
immature cells chop them into fragments of the cells that have been educated by ins into a strategy to fight cancer.
(antigens) that can be recognized by the dendritic cells become memory cells Cancer cells are abnormal and as such
rest of the immune system [see illustra- that remain in the body for years per- are thought to generate molecules that
tion on next two pages]. The cells use haps decades to combat the invader in healthy cells dont. If researchers could de-
Bacteria enter
cut in the skin.
Skin
Lung Lymph node
Epidermis
Dermis
Type 1 cytokine
HELPER
T CELL
KILLER
T CELL T cell
receptors Adhesion protein
Antigens
MEMORY
T CELL Costimulatory
molecule
MHC class II
MHC class I
Antibody Antigen
MHC class I
Antigen
After traveling to the
lymph nodes in a fluid MHC class II
called lymph, dendritic
cells activate other cells
of the immune system
that are capable of
recognizing the antigens
they carry. The activation
readies the immune cells
to fight invaders bearing
the antigens.
MEMORY
B CELL
LYMPH NODE
B CELL
Unknown signal
TERESE WINSLOW
vise drugs or vaccines that exclusively tar- the dendritic cells pick up the antigens, more than two of the antigens.
geted those aberrant molecules, they could chop them up and present them on their Scientists are now working to refine
combat cancer more effectively while leav- surfaces. When injected back into the pa- the approach and test it on larger num-
ing normal cells and tissues alonethere- tients, the antigen-loaded dendritic cells bers of patients. So far cancer vaccines
by eliminating some of the pernicious side are expected to ramp up patients im- based on dendritic cells have been tested
effects of chemotherapy and radiation, mune response against their own tumors. only in patients with advanced cancer. Al-
such as hair loss, nausea and weakening of Various researchersincluding Frank though researchers believe that patients
the immune system caused by destruction O. Nestle of the University of Zurich and with earlier-stage cancers may respond
of the bone marrow. Ronald Levy and Edgar G. Engleman of better to the therapy their immune sys-
Antigens that occur only on cancerous Stanford University, as well as scientists tems have not yet tried and failed to erad-
cells have been hard to find, but re- at several biotechnology companies [see icate their tumorseveral potential prob-
searchers have succeeded in isolating sev- box above] are testing this approach lems must first be considered.
eral of them, most notably from the skin against cancers as diverse as melanoma, Some researchers fear that such vac-
cancer melanoma. In the early 1990s B cell lymphoma, and tumors of the cines might induce patients immune sys-
Thierry Boon of the Ludwig Cancer In- prostate and colon. There have been tems to attack healthy tissue by mistake.
stitute in Brussels, Steven A. Rosenberg of glimmers of success. In September 2001, For instance, vitiligo white patches on
the National Cancer Institute and their for instance, my co-workers and I, in col- the skin caused by the destruction of nor-
colleagues independently identified mela- laboration with Steinmans group, re- mal pigment-producing melanocytes
noma-specific antigens that are currently ported that 16 of 18 patients with ad- has been observed in melanoma patients
being targeted in a variety of clinical tri- vanced melanoma to whom we gave in- who have received the earliest antime-
als involving humans. jections of dendritic cells loaded with lanoma vaccines. Conversely, the tumors
Such trials generally employ vaccines melanoma antigens showed signs in lab- might mutate to escape the immune
made of dendritic cell precursors that oratory tests of an enhanced immune re- onslaught engendered by a dendritic cell
have been isolated from cancer patients sponse to their cancer. What is more, tu- vaccine. Tumor cells could accomplish
and grown in the laboratory together mor growth was slowed in the nine pa- this evasion by no longer making the
with tumor antigens. During this process, tients who mounted responses against antigens the vaccine was designed to
stimulate the immune system against.
This problem is not unique to dendritic
THE AUTHOR
JACQUES BANCHEREAU has directed the Baylor Institute for Immunology Research in Dal-
las since 1996. The institute aims to manipulate the human immune system to treat can- cells, though: the same phenomenon can
cer as well as infectious and autoimmune diseases. Before 1996 Banchereau led the Scher- occur with traditional cancer therapies.
ing-Plough Laboratory for Immunology Research in Dardilly, France. He obtained his Ph.D. In addition, tailoring a dendritic cell
in biochemistry from the University of Paris. Banchereau holds many patents on immuno- vaccine to fight a particular patients tu-
logical techniques and is a member of the scientific advisory board of Merix Bioscience, a mors might not be economically feasible.
biotechnology company based in Durham, N.C. But many scientists are working to cir-
cumvent the costly and time-consuming as rheumatoid arthritis, type 1 diabetes ecule that can bind to the outer coat of
steps of isolating cells from patients and and systemic lupus erythematosus. Last HIV. These cells pick up HIV as they reg-
manipulating them in the laboratory for year my colleagues and I reported that ularly prowl the mucous membranes and
reinjection. dendritic cells from the blood of people deep tissues. When they travel to the
One approach involves prompting with lupus are unnaturally active. Cells lymph nodes, they unwittingly deliver the
dendritic cell precursors already present from these patients release high amounts virus to a large concentration of T cells.
in a persons body to divide and start or- of interferon-alpha, an immune-stimu- Drugs that block the interaction between
chestrating an immune response against lating protein that causes precursors to DC-SIGN and HIV might slow the pro-
their tumors. David H. Lynch of Immun- grow into mature dendritic cells while gression of AIDS.
ex in Seattle (recently acquired by Amgen still in the bloodstream. The mature cells Other infectious diseases including
in Thousand Oaks, Calif.) and his co- then ingest DNA, which is present in un- malaria, measles and cytomegalovirus
workers have discovered a cytokine that usual amounts in the blood of people also manipulate dendritic cells for their
causes mice to make more dendritic cells, with lupus, and that in turn causes the in- own ends. Red blood cells that have been
which eventually induce the animals to re- dividuals immune system to generate an- infected by malaria parasites, for instance,
ject grafted tumors. Other scientists, in- tibodies against his or her own DNA. bind to dendritic cells and prevent them
cluding Drew M. Pardoll of Johns Hop- These antibodies result in the life-threat- from maturing and alerting the immune
kins University, have observed that tumor ening complications of lupus when they system to the presence of the invaders.
cells that have been genetically engineered lodge in the kidneys or the walls of blood Several groups of researchers are now de-
to secrete large amounts of cytokines that vessels. Accordingly, we propose that vising approaches to prevent such mi-
activate dendritic cells have the most po- blocking interferon-alpha might lead to crobes from hijacking dendritic cells; some
tential as cancer vaccines. a therapy for lupus by preventing den- are even seeking to use supercharged den-
dritic cell activation. A similar strategy dritic cells to fight the infections.
Shutting Immunity Down might prevent organ transplant recipients As we learn more about the mole-
I N T H E M E A N T I M E , other scientists from rejecting their new tissues. cules that control dendritic cells, we will
are looking at ways to turn off the activ- A new treatment for AIDS might also find ways to harness their therapeutic po-
ity of dendritic cells in instances where rest on a better understanding of den- tential. The increasing number of scien-
they exacerbate disease instead of fight- dritic cells. In 2000 Carl G. Figdor and tists and corporations working on den-
ing it. Usually, in a phenomenon known Yvette van Kooyk of the University Med- dritic cells portends that we will soon be
as central tolerance, an organ in the chest ical Center St. Radboud in Nijmegen, the able to maximize the biological power of
called the thymus gets rid of young T Netherlands, identified a subset of den- these cells to treat and prevent the dis-
cells that happen to recognize the bodys dritic cells that makes DC-SIGN, a mol- eases that plague humankind.
own components as foreign before they
have a chance to circulate. Some in- MORE TO E XPLORE
evitably slip through, however, so the Dendritic Cells and the Control of Immunity. Jacques Banchereau and Ralph M. Steinman in
JACQUES BANCHEREAU
body has a backup mechanism for re- Nature, Vol. 392, pages 245252; March 19, 1998.
straining their activity. Dendritic Cells as Vectors for Therapy. Jacques Banchereau, Beatrice Schuler-Thurner,
But this mechanism, termed periph- A. Karolina Palucka and Gerold Schuler in Cell, Vol. 106, No. 3, pages 271274; August 10, 2001.
eral tolerance, appears to be broken in Background information on the immune system and on experimental cancer therapies such as
patients with autoimmune disorders such those using dendritic cells can be found on the American Cancer Societys Web site: www.cancer.org
New
LightonMedicine
Stories of vampires date back thousands of years.
Our modern concept stems from Bram Stokers quirky classic Dracula and Holly-
woods Bela Lugosi the romantic, sexually charged, blood-sucking outcast with
a fatal susceptibility to sunlight and an abhorrence of garlic and crosses. In con-
trast, vampires of folklore cut a pathetic figure and were also known as the undead.
In searching for some underlying truth in vampire stories, researchers have specu-
lated that the tales may have been inspired by real people who suffered from a rare
blood disease, porphyria. And in seeking treatments for this disorder, scientists
have stumbled on a new way to attack other, more common serious ills.
Porphyria is actually a collection of related diseases in which pigments called
porphyrins accumulate in the skin, bones and teeth. Many porphyrins are benign
in the dark but are transformed by sunlight into caustic, flesh-eating toxins. With- LIGHT-ACTIVATED DRUGS used in
photodynamic therapy could treat
out treatment, the worst forms of the disease (such as congenital erythropoietic por- diseases of the eye, cancers such
phyria) can be grotesque, ultimately exacting the kind of hideous disfigurement one as those of the esophagus, and
might expect of the undead. The victims ears and nose get eaten away. Their lips coronary artery disease.
CREDIT
By Nick Lane
COPYRIGHT 2004 SCIENTIFIC AMERICAN, INC.
and gums erode to reveal red, fanglike teeth. Their skin acquires absorbs the energy of sunlight in photosynthesis, is a porphyrin,
a patchwork of scars, dense pigmentation and deathly pale as is heme, which is at the heart of the oxygen-transporter pro-
hues, reflecting underlying anemia. Because anemia can be tein hemoglobin and of many enzymes vital for life, including
treated with blood transfusions, some historians speculate that cytochrome oxidase (which generates energy by transferring
in the dark ages people with porphyria might have tried drink- electrons to oxygen in a critical step of cellular respiration).
ing blood as a folk remedy. Whatever the truth of this claim, Porphyria arises because of a flaw in the bodys heme-mak-
those with congenital erythropoietic porphyria would certain- ing machinery. The body produces heme and other porphyrins
ly have learned not to venture outside during the day. They in a series of eight coordinated stages, each catalyzed by a sepa-
might have learned to avoid garlic, too, for some chemicals in rate enzyme. Iron is added at the end to make heme. In porphyria,
garlic are thought to exacerbate the symptoms of the disease one of the steps does not occur, leading to a backlog of the in-
porphyria, turning a mild attack into an agonizing reaction. termediate compounds produced earlier in the sequence. The
While struggling to find a cure for porphyria, scientists came body has not evolved to dispose of these intermediates efficient-
to realize that porphyrins could be not just a problem but a tool ly, so it dumps them, often in the skin. The intermediates do not
for medicine. If a porphyrin is injected into diseased tissue, such damage the skin directly, but many of them cause trouble indi-
as a cancerous tumor, it can be activated by light to destroy that rectly. Metal-free porphyrins (as well as metalloporphyrins con-
tissue. The procedure is known as photodynamic therapy, or taining metals that do not interact with the porphyrin ring) can
PDT, and has grown from an improbable treatment for can- become excited when they absorb light at certain wavelengths;
cer in the 1970s to a sophisticated and effective weapon against their electrons jump into higher-energy orbitals. The molecules
a diverse array of malignancies today and, most recently, for can then transmit their excitation to other molecules having the
macular degeneration and pathologic myopia, common caus- right kind of bonds, especially oxygen, to produce reactive sin-
es of adult blindness. Ongoing research includes pioneering glet oxygen and other highly reactive and destructive molecules
treatments for coronary artery disease, AIDS, autoimmune dis- known as free radicals. Metal-free porphyrins, in other words,
eases, transplantation rejection and leukemia. are not the agents, but rather the brokers, of destruction. They
catalyze the production of toxic forms of oxygen.
Molecular Mechanisms Photosensitive reactions are not necessarily harmful. Their
THE SUBSTANCES AT THE HEART of porphyria and pho- beneficial effects have been known since ancient times. In par-
todynamic therapy are among the oldest and most important of ticular, some seeds and fruits contain photosensitive chemicals
all biological molecules, because they orchestrate the two most (photosensitizers) called psoralens, which indirectly led scien-
critical energy-generating processes of life: photosynthesis and tists to experiment with porphyrins. Psoralens have been used
oxygen respiration. Porphyrins make up a large family of close- to treat skin conditions in Egypt and India for several thousand
ly related compounds, a colorful set of evolutionary variations years. They were first incorporated into modern medicine by
on a theme. All porphyrins have in common a flat ring (com- Egyptian dermatologist Abdel Monem El Mofty of Cairo Uni-
posed of carbon and nitrogen) with a central hole, which pro- versity, just over 50 years ago, when he began treating patients
vides space for a metal ion such as iron or magnesium to bind to with vitiligo (a disease that leaves irregular patches of skin with-
it. When aligned correctly in the grip of the porphyrin rings, out pigment) and, later, those with psoriasis using purified pso-
these metal atoms catalyze the most fundamental energy-gener- ralens and sunlight. When activated by light, psoralens react
ating processes in biology. Chlorophyll, the plant pigment that with DNA in proliferating cells to kill them.
Two American dermatologists, Aaron B. Lerner of Yale
Overview/Light Therapy University and Thomas B. Fitzpatrick of Harvard University,
were struck by the potential of psoralens. In the 1960s they
In photodynamic therapy, light-activated chemicals showed that psoralens are activated by ultraviolet (UVA) rays,
called porphyrins are used to destroy fast-growing cells and the researchers later refined psoralen therapy using an ul-
and tissue. Doctors could apply the treatment to a variety traviolet lamp similar to those used in solariums today. Their
of ailments, including age-related macular degeneration, method became known as PUVA (short for psoralen with
tumors and atherosclerotic plaques. UVA) and is now one of the most effective treatments for pso-
A few porphyrin drugs are on the market, and several riasis and other skin conditions.
others are undergoing human trials.
Researchers got the idea for photodynamic therapy from A Way to Kill Cancer Cells?
their knowledge of the rare disease porphyria, in which I N T H E E A R L Y 1 9 7 0 s the success of PUVA impressed
porphyrins accumulate in the skin and certain organs. Thomas J. Dougherty of the Roswell Park Cancer Institute in
Unless the disease is managed, victims of the severest Buffalo, N.Y., leading him to wonder if a variant of it could
type of porphyria can become disfigured, leading some be effective against cancer. Activated psoralens can kill rogue
researchers to speculate that they may have inspired cells to settle inflammation, but in comparison with porphyrins
medieval vampire legends. they are not potent photosensitizers. If psoralens could kill in-
dividual cells, could porphyrins perhaps devour whole tumors?
27 SCIENTIFIC AMERICAN EXCLUSIVE ONLINE ISSUE OCTOBER 2004
CHLOROPHYLL
No metal
Iron
Magnesium
His idea was the beginning of true photodynamic therapy, in PORPHYRINS all have in common a flat ring, mainly composed of carbon
which photosensitizers catalyze the production of oxygen free and nitrogen, and a central hole where a metal ion can sit. The basic ring
radicals. It was built on earlier work, which revealed two med- ( far left) becomes caustic when exposed to light; molecules useful for
ically useful properties of the porphyrins: they accumulate se- photodynamic therapy also share this trait. Nontoxic examples include
lectively in cancer cells and are activated by red light, which heme (a component of the oxygen transporter hemoglobin) and the
penetrates more deeply into biological tissues than do shorter chlorophyll that converts light to energy in plants.
wavelengths, such as blue light or UVA.
Dougherty injected a mixture of porphyrins into the blood- self can cause this problem if it accumulates to such high levels
stream of mice with mammary tumors. He then waited a cou- that it absorbs all the light in the superficial layers of the tumor,
ple days for the porphyrins to build up in the tumors before thus preventing penetration into the deeper layers.
shining red light on them. His early setup was primitive and Many of these difficulties could not be resolved without the
passed the light from an old slide projector through a 35mm help of specialists from other disciplines. Chemists were need-
slide colored red. His results were nonetheless spectacular. The ed to create new, synthetic porphyrins, ones that had greater
light activated the porphyrins within the tumor, which trans- selectivity for tumors and greater potency and that would be
ferred their energy to oxygen in cells to damage the surround- activated by wavelengths of light able to reach farther into tis-
ing tissues. In almost every case, the tumors blackened and died sues and tumors. (For each porphyrin, light activation and ab-
after the light treatment. There were no signs of recurrence. sorption occur only at particular wavelengths, so the trick is
Dougherty and his colleagues published their data in 1975 to design a porphyrin that has its absorption maximum at a
in the Journal of the National Cancer Institute, with the brave wavelength that penetrates into biological tissues.) Physicists
title Photoradiation Therapy II: Cure of Animal Tumors with were needed to design sources that could produce light of par-
Hematoporphyrin and Light. Over the next few years they re- ticular wavelengths to activate the new porphyrins or that could
fined their technique by using a low-power laser to focus red be attached to fine endoscopes and catheters or even implant-
light onto the tumors. They went on to treat more than 100 pa- ed in tissues. Pharmacologists were needed to devise ways of re-
tients in this way, including people with cancers of the breast, ducing the time that porphyrins spent circulating in the blood-
lung, prostate and skin. Their outcomes were gratifying, with a stream, thereby restricting photosensitive side effects. Finally,
complete or partial response in 111 of 113 tumors. clinicians were needed to design trials that could prove an ef-
Sadly, though, cancer is not so easily beaten. As more physi- fect and determine the best treatment regimens.
cians started trying their hand with PDT, some serious draw- The ideal drug would be not only potent and highly selective
backs began to emerge. The affinity of porphyrins for tumors for tumors but also broken down quickly into harmless com-
turned out to be a bit of an illusion porphyrins are taken up by pounds and excreted from the body. The first commercial prepa-
any rapidly proliferating tissue, including the skin, leading to ration, porfimer sodium (Photofrin), was approved by the U.S.
photosensitivity. Although Doughertys original patients were Food and Drug Administration for the treatment of various can-
no doubt careful to avoid the sun, nearly 40 percent of them re- cers. Although it has been helpful against certain cancers (in-
ported burns and skin rashes in the weeks after PDT.
Potency was another issue. The early porphyrin prepara-
THE AUTHOR
Photoreceptors
1 porphyrin (green) is injected into a
patients arm. It takes just 15 minutes for
Retinal pigment Fast-growing vascular tissue
of the retina the porphyrin to accumulate in abnormal
epithelium
blood vessels under the macula, which is
Normal blood vessels Area damaged the central part of the retina and
by disease responsible for color vision.
1 Here, in an
experimental
therapy, an optical
Atherosclerotic
plaque containing
a porphyrin (green)
Battling Blindness
O N E T H I N G I T C O U L D D O , for instance, was combat age-
fiber has been Artery related macular degeneration (AMD), the most common cause
threaded into an of legal blindness in our maturing Western population [see
artery in which a The Challenge of Macular Degeneration, by Hui Sun and Je-
porphyrin has remy Nathans; Scientific American, October 2001]. Most
accumulated in people who acquire AMD have a benign form and do not lose
atherosclerotic their sight, but about a tenth have a much more aggressive type
plaques. called wet AMD. In this case, abnormal, leaking blood vessels,
like miniature knots of varicose veins, grow underneath the reti-
na and ultimately damage the sharp central vision required for
Light
source
reading and driving. As the disease progresses, central vision
is obliterated, making it impossible to recognize peoples faces
or the details of objects.
Most attempts to hinder this grimly inexorable process have
2 The fiber
produces red
light, activating
failed. Dietary antioxidants may be able to delay the onset of
the disorder but have little effect on the progression of estab-
the porphyrin. lished disease. Until recently, the only treatment proved to slow
the progression of wet AMD was a technique called laser pho-
tocoagulation. The procedure involves applying a thermal laser
to the blood vessels to fuse them and thus halt their growth. Un-
fortunately, the laser also burns the normal retina and so de-
stroys a small region to prevent later loss of vision in the rest
of the eye. Whether this is worth it depends on the area of the
retina that needs to be treated. For most people diagnosed with
wet AMD, the area is located below the critical central part of
vision or is already too large to benefit from laser coagulation.
Against this depressing backdrop, researchers at Harvard
and at the biotechnology firm QLT, Inc., in Vancouver, B.C.,
reasoned that PDT might halt the growth of these blood vessels
3 Over the
course of a
few days, the
and delay or even prevent blindness. If porphyrins could accu-
mulate in any rapidly proliferating tissue the very problem in
porphyrin destroys cancer then perhaps they could also accumulate in the blood
unwanted plaques. vessels growing under the retina. Verteporfin, a novel synthet-
ic porphyrin, seemed promising because it had a good track
record in preclinical, animal studies at QLT and at the Univer-
sity of British Columbia in the late 1980s and early 1990s.
Verteporfin accumulates in abnormal retinal vessels re-
HYBRID MEDICAL ANIMATION
Papillary
1.0 dermis problems of conventional angioplasty, notably the restenosis (re-
narrowing) of treated arteries. The procedure involves inject-
ing a porphyrin into the bloodstream, waiting for it to build up
1.5 in the damaged arterial walls and then illuminating the artery
Porphyrin from the inside, using a tiny light source attached to the end of
activation
2.0 a catheter. The light activates the porphyrins in the plaques, de-
to 12 cm
Reticular stroying the abnormal tissues while sparing the normal walls
dermis Percentage of
2.5 light penetration of the artery. The results of a small human trial testing the safe-
(width of cone) ty of the synthetic porphyrin motexafin lutetium were present-
ed in March 2002 by Jeffrey J. Popma of Brigham and Womens
3.0
Subcutaneous Hospital at the annual meeting of the American College of Car-
fatty tissue diology. Although it is still early in the testing process, the find-
3.5 ings fuel hopes for the future: the procedure was safe, and its suc-
EACH WAVELENGTH OF LIGHT reaches a different depth in tissues, and any cess at preventing restenosis increased as the dosage increased.
given porphyrin absorbs light at specific wavelengths. A porphyrin Accumulation of porphyrins in active and proliferating cells
activated by deeper-penetrating light might be best for treating an internal raises the possibility of treating other conditions in which ab-
tumor. In contrast to porphyrins, the psoralens used in PUVA treatments for normal cell activation or proliferation plays a role among
psoriasis are activated by near-ultraviolet light (400 nanometers), which them, infectious diseases. Attempts to treat infections with the
barely penetrates the skin. pigments had long been frustrated by a limited effect on gram-
negative bacteria, which have a complex cell wall that obstructs
can be given six or seven times over a three-year period with- the uptake of porphyrins into these organisms. One solution, de-
out damaging a healthy retina. For people with the most ag- veloped by Michael R. Hamblin and his colleagues at Harvard,
gressive form of AMD (with mostly classic lesions), verte- involved attaching a polymer usually polylysine, a repetitive
porfin halved the risk of moderate or serious vision loss over a chain of the amino acid lysine to the porphyrin. The polymer
two-year period. The effect is sustained over at least three or disrupts the lipid structure of the bacterial cell wall, enabling the
four years: patients who are not treated lose as much vision in porphyrins to gain entry to the cell. Once inside, they can be ac-
three months as those treated with verteporfin lose in three tivated by light to kill the bacteria. In recent studies of animals
years. The treatment also worked, though not as well, for peo- with oral infections and infected wounds, the altered porphyrin
ple with less aggressive types of AMD and for those with re- showed potent antimicrobial activity against a broad spectrum
lated diseases such as pathologic myopia and ocular histoplas- of gram-negative and gram-positive bacteria. As antibiotic re-
mosis syndrome. Only a small proportion of patients suffered sistance becomes more intractable, targeted antimicrobial PDT
from sunburns or other adverse reactions, rarely more than 24 could become a useful weapon in the medical arsenal.
hours after the procedure was done. Several other, related photodynamic methods hinge on the
Some participants in the trials gained little benefit from PDT. finding that activated immune cells take up greater amounts
For many of them, the disease may have already progressed too of photosensitizing drugs than do quiescent immune cells and
far. A reanalysis of clinical data presented by Bressler in April red blood cells, sparing the quiet cells from irreversible dam-
2002 at the International Congress of Ophthalmology in Syd- age. In most infections, nobody would wish to destroy activat-
ney, Australia, showed that smaller lesions respond much bet- ed immune cells: they are, after all, responsible for the bodys
ter to treatment than older, larger ones, implying that early de- riposte to the infection. In these cases, targeting immune cells
tection and treatment may optimize the benefits of PDT. would be equivalent to friendly fire and would give the in-
fection free rein to pillage the body.
Other Treatment Avenues In AIDS, however, the reverse is true. The AIDS virus, HIV,
THE SUCCESS OF OPHTHALMIC PDT has inspired research infects the immune cells themselves. Targeting infected immune
activity in other fields but also reveals the drawbacks of the cells would then be more like eliminating double agents. In the
treatment. In particular, even red light penetrates no more than laboratory, HIV-infected immune cells take up porphyrins,
HYBRID MEDICAL ANIMATION
a few centimeters into biological tissues [see illustration above]. thereby becoming vulnerable to light treatment. In patients, the
This limitation threatens the utility of PDT in internal medi- light could be applied either by withdrawing blood, illuminat-
cine its significance might seem to be skin deep. There are ing it and transfusing it back into the body (extracorporeal pho-
ways of turning PDT inward, however. One ingenious idea is totherapy) or by shining red light onto the skin, in what is called
called photoangioplasty, which is now being used to treat coro- transdermal phototherapy. In the transdermal approach, light
nary artery disease. would eliminate activated immune cells in the circulation as
Photofrin Cancers of the esophagus and lung, AXCAN SCANDIPHARM On the market for esophageal cancer
(porfimer sodium) high-grade dysplasia from Birmingham, Ala. and nonsmall cell lung cancer; awaiting
Barretts esophagus FDA decision on high-grade dysplasia
Metvix Actinic keratosis, basal cell skin PHOTOCURE Awaiting final FDA approval for actinic
(methylaminolevulinic cancer and squamous cell Oslo, Norway keratosis; in Phase III trials (large
acid) skin cancer studies of efficacy) for skin cancers
PhotoPoint SnET2 Age-related macular MIRAVANT MEDICAL TECHNOLOGIES Phase III trials have been
(tin ethyl etiopurpurin) degeneration Santa Barbara, Calif. completed
verteporfin Basal cell cancer, androgenetic QLT, INC. In Phase III trials for basal cell cancer;
alopecia (male pattern baldness) as QLT0074, in Phase I trials (tests of
and prostatic hyperplasia safety in small numbers of patients)
(enlarged prostate) for other conditions
they passed through the skin. Whether the technique will be po- dure might work either extracorporeally or transdermally.
tent enough to eliminate diseased immune cells in HIV-infect- Much of this research is in late-stage preclinical or early clini-
ed patients remains an open question. cal trials. For all the cleverness in exploring possible medical
Autoimmune diseases, rejection of organ transplants, and applications, though, we can only hope that more extensive
leukemias are also all linked by the common thread of activat- clinical studies will bear fruit.
ed and proliferating immune cells. In autoimmune diseases,
components of our own body erroneously activate immune MORE TO E XPLORE
cells. These activated clones then proliferate in an effort to de- The Colours of Life: An Introduction to the Chemistry of Porphyrins and
stroy the perceived threat say, the myelin sheath in multiple Related Compounds. L. R. Milgrom. Oxford University Press, 1997.
sclerosis or the collagen in rheumatoid arthritis. When organs Lethal Weapon. P. Moore in New Scientist, Vol. 158, No. 2130,
pages 4043; April 18, 1998.
are implanted, activated immune cells may multiply to reject
Verteporfin Therapy for Subfoveal Choroidal Neovascularization in
the foreign tissue the transplanted organ or even the body tis- Age-Related Macular Degeneration: Three-Year Results of an Open-
COMPILED BY TARIQ MALIK
sues of the new host, in the case of bone marrow transplants. Label Extension of 2 Randomized Clinical Trials. TAP Report No. 5.
In leukemia, immune cells and their precursors in the bone mar- M. S. Blumenkranz et al. in Archives of Ophthalmology, Vol. 120, No. 10,
pages 13071317; October 2002.
row produce large numbers of nonfunctional cells. In each in-
Oxygen: The Molecule That Made the World. Nick Lane. Oxford University
stance, PDT could potentially eliminate the unwanted immune Press (in press).
cells, while preserving the quiescent cells, to maintain a normal An overview of the nature of and treatments for porphyria can be found
immune response to infection. As in HIV infection, the proce- at www.sciam.com/exploredirectory.cfm
V
iruses are some of the most insidious creations in na-
ture. They travel light: equipped with just their genet-
ic material packed tightly inside a crystalline case of
protein, they latch onto cells, insert their genes, and co-opt the
cells gene-copying and protein-making machinery,
using them to make billions of copies of themselves.
Once formed, the new viruses percolate to the cell
surface, pinch off inside minuscule bubbles of cell membrane
and drift away, or else they continue reproducing until the cell
finally bursts. In any case, they go on to infect and destroy oth-
er cells, resulting in diseases from AIDS to the common cold.
Different viruses cause different diseases in part because each
virus enters a cell by first attaching to a specific suction-cuplike
receptor on its surface. Liver cells display one kind of receptor
used by one family of viruses, whereas nerve cells display an-
other receptor used by a different viral family, so each type of
virus infects a particular variety of cell. Cancer researchers have
envied this selectivity for years: if they could only target cancer
therapies to tumor cells and avoid damaging normal ones, they
might be able to eliminate many of the noxious side effects of
cancer treatment.
by bursting them open or deliver genes that make the and other viral vectors, or gene-delivery systems, to improve
cells more susceptible to traditional chemotherapies. their safety and reduce the chances that such a tragedy might oc-
The same types of viruses used in virotherapy can also be cur again. It is perhaps even more essential for researchers, such
labeled with fluorescent or radioactive tags. Once as ourselves, who are investigating virotherapy to develop safer,
delivered into the body, they home in on cancer cells. In more targeted vectors, because virotherapy by definition aims
the future, physicians might be able to use this imaging to kill the cells the viruses infect, not just insert a therapeutic gene
technique to detect the presence of tiny tumors. into them. Killing the wrong cells could be dangerous.
Adenoviruses bring with them characteristics that can make
them riskier or safer, depending on the circumstances. Nearly the hapless cell engulfs it in a membrane sac and pulls it inside.
everyone has been exposed at one time or another to adeno- As the sac disintegrates, the viral capsid travels to a pore in the
viruses, so almost all of us carry antibodies the immune system cells nucleus and injects its own DNA. Soon the viral DNA di-
makes to target them for destruction. Accordingly, shots of ade- rects the cell to make copies of the viral DNA, synthesize viral
noviruses as cancer therapies might cause severe, flulike symp- proteins and combine the two into billions of new adenovirus-
toms if the body recognizes them as foreign and ramps up an im- es. When the cell is full to capacity, the virus activates a death
mune response to eradicate them. (Wiping out the viruses would gene and prompts the cell to burst, releasing the new viruses
also squelch the therapy.) At the same time, recognition by the to spread to other cells.
immune system ensures that the viruses do not reproduce out of The viruses can also be engineered more directly. In this re-
control. Investigators are now designing various therapeutic ap- gard, Curiels group at the University of Alabamas Gene Ther-
proaches to optimize the efficacy of virotherapy and minimize apy Center has designed adenoviruses that bind to cellular pro-
the chances that adenoviruses will cause side effects. These teins called integrins. These molecules help cells stick to the
strategies include giving immunosuppressive drugs at the time network of connective tissue, called the extracellular matrix,
of virotherapy and modifying the adenoviruses so that they do that organizes the cells into cohesive tissues. Although inte-
not trigger a reaction by the immune system. grins are also made by healthy cells, cancer cells produce them
in abundance as they become metastatic and begin to squeeze
Homing In on the Target through tissue layers and travel throughout the body. The Uni-
two main strategies to versity of Alabama research group has had encouraging results
THOMAS R. BROKER AND LOUISE T. CHOW University of Alabama at Birmingham
collateral damage. In the first approach, termed transduction- cancers. The viruses homed in on the ovarian tumor cells
al targeting, researchers are attempting to adapt the viruses so
that they preferentially infect, or transduce, cancer cells. The
THE AUTHORS
Cell bursts,
and virus
infects and
Viral kills other
outer
coat cancer cells
proteins
Adapter molecule
on engineered
adenovirus
Receptor
Normal made only by
adenovirus tumor cells
receptor
NORMAL CANCER
CELL CELL
VIRAL DNA
CELL DNA
TERESE WINSLOW
CELL DNA
Engineered adenovirus
with tumor-specific Cell bursts,
promoter links to and virus
essential virus gene infects and
kills other
cancer cells
Promoter
Infection occurs,
but normal cell does
not have switch to
turn on viral gene.
Virus cannot replicate
or kill cell
NORMAL CANCER
CELL CELL
Tumor-
VIRAL DNA specific
promoter
But Is It Safe?
Many approaches to virotherapy use adenoviruses, which caused a death in a clinical
trial of gene therapy four years ago
IN SEPTEMBER 1999 18-year-old Jesse Gelsinger died after receiving an infusion of adenoviruses into his liver. He had a mild form of
an inherited liver disease called ornithine transcarbamylase deficiency (OTCD) and was participating in a clinical trial of a new gene
therapy to use adenoviruses to ferry a corrected copy of the gene encoding OTCD into his liver cells. Unfortunately, four days after an
infusion of the viruses, he died of acute respiratory distress syndrome and multiple organ failure, apparently caused by an
overwhelming immune reaction to the large dose of adenoviruses he had been administered as part of the trial.
Although Gelsingers death was part of a gene therapy trial, the tragedy also has ramifications for the new field of virotherapy.
Gene therapy uses crippled versions of viruses such as adenovirus to introduce a new gene into cells; virotherapy employs actively
replicating viruses (which may or may not contain added genes) to kill specific types of cells. Both, however, rely heavily on
adenoviruses.
Gelsingers autopsy showed that the engineered adenoviruses had spread to his spleen, lymph nodes and bone marrow, and an
examination of his records revealed that his liver function was probably too impaired for him to be a volunteer in the trial. A number of
scientists have also suggested that he might have mounted such an extreme immune reaction because he had previously been infected
with a naturally occurring adenovirus.
Since Gelsingers death, gene therapists and virotherapists alike have focused on refining adenoviruses to make them safer. But
researchers are still unsure why Gelsinger reacted so violently to the adenoviral infusions: a second patient participating in the same
clinical trial tolerated a similar dose of the viruses. And dozens of other people worldwide have been treated so far with adenoviruses
with no serious side effects.
A National Institutes of Health report generated in the aftermath of Gelsingers demise recommends that all participants in such
clinical trials be monitored closely for toxic reactions before and after the infusion of therapeutic viruses. It also stipulates that
volunteers be screened for any predisposing conditions that would increase their sensitivity for the viruses.
D.M.N. and D.T.C.
fail-safe mechanisms would be expected to be less likely to But physicians will also need to track the activity of virothera-
harm normal cells. There are no results at present, however, pies in a patients body to best assess how well the strategies are
to demonstrate that a combination of approaches makes virus- working and refine them further. Virotherapists are now team-
es more targeted. ing with radiologists to establish novel imaging technologies to
A further strategy for targeting virotherapy makes the most easily measure how effectively a given virotherapy is replicating.
of one of cancers hallmarks: the ability of tumor cells to divide The imaging strategies involve inserting a gene that governs
again and again in an uncontrolled manner. Healthy cells make the production of a tracer molecule into a virus or virus-infect-
proteins that serve as natural brakes on cell division notably, ed cell. The tracer can be either a fluorescent protein that can
the retinoblastoma (Rb) and p53 proteins. As cells turn can- be observed directly or one that binds readily to the radionu-
cerous, however, the genes that code for one or the other of clides used in standard radiological imaging techniques. The flu-
these proteins become mutated or otherwise inactivated. Cer- orescent protein might work best for cancers that are accessi-
tain viruses, including adenovirus, interfere with the braking ble by an endoscope, such as cancers of the larynx. Physicians
mechanisms of a normal cell by making proteins that stick to could peer into the endoscope and see exactly where the virus-
and inactivate Rb or p53. They do this because they can repli- es and therefore, cancer cells are by looking for fluorescence.
cate only in cells that are preparing to divide. So far the approach has worked best with viruses that do not kill
Several research groups and biotechnology companies have cells, however. Nevertheless, we are convinced that such sophis-
engineered adenoviruses that fail to make the Rb or p53 block- ticated imaging technologies will enable scientists to draw more
ers. Normal cells, which make these blockers, will stall the repli- meaningful conclusions from future clinical trials of virotherapy.
cation of these viruses by putting the brake on cell division. But In 1995 gene therapy pioneer W. French Anderson of the
these viruses will replicate in cells in which the Rb or p53 pro- University of Southern California School of Medicine predicted
teins are already disabled cancer cells and kill them. Curiel in this magazine that by 2000 ... early versions of injectable vec-
is planning clinical trials of the approach for ovarian cancer. tors that target specific cells will be in clinical trials. These tri-
Researchers are also arming therapeutic viruses with genes als indeed began on schedule, as well as some he could not have
that make the cells they infect uniquely susceptible to chemo- envisioned then. We envision a substantial role for viruses that
therapy. The technique involves splicing into the viruses genes is, therapeutic viruses in 21st-century medicine.
that encode enzymes that turn nontoxic precursors, or pro-
drugs, into noxious chemotherapies. In one example, which MORE TO E XPLORE
was reported in 2002, Andr Lieber of the University of Wash- Gene Therapy: Designer Promoters for Tumour Targeting.
ington and his co-workers designed adenoviruses to carry genes D. M. Nettelbeck, V. Jrme and R. Mller in Trends in Genetics, Vol. 16,
pages 174181; 2000.
encoding the enzymes capable of converting innocuous prodrugs Replicative Adenoviruses for Cancer Therapy. R. Alemany, C. Balagu
into the anticancer compounds camptothecin and 5-fluoro- and D. T. Curiel in Nature Biotechnology, Vol. 18, pages 723727; 2000.
uracil. The scientists engineered the viruses so that they could Vector Targeting for Therapeutic Gene Delivery. Edited by D. T. Curiel
make the enzymes only in actively dividing cells, such as cancer and J. T. Douglas. John Wiley & Sons, 2002.
cells. When they injected the viruses and the prodrugs into mice Cytolytic Viruses as Potential Anti-Cancer Agents. C.J.A. Ring
in Journal of General Virology, Vol. 83, pages 491502; 2002.
bearing implanted human colon or cervical cancer cells, they Gene therapy clinical trials database of Journal of Gene Medicine:
found that the viruses reproduced and spread in the tumors. www.wiley.com/legacy/wileychi/genmed/clinical/
Such smart virotherapies are the vanguard of the future. American Society of Gene Therapy: www.asgt.org
40 SCIENTIFIC AMERICAN EXCLUSIVE ONLINE ISSUE OCTOBER 2004
Hormone Hysteria?
HORMONE REPLACEMENT THERAPY MAY NOT BE SO BAD BY DENNIS WATKINS
ostmenopausal women have for decades relied on estro- yprogesterone acetate. This pill, taken daily, was the most wide-
After being poked, scanned, drugged and radiated, your doc tells against Health Fraud (www.ncahf.org), and Wallace Sampsons
you nothing more can be done to cure what ails you. Why not journal The Scientific Review of Alternative Medicine.
try an alternative healing modality? Whats the harm? Most alternatives, however, slip under the scientific peer-
I started thinking about this question in 1991, when my review radar. This is why it is alarming that, according to the
normally intelligent mother presented to a psychiatrist symp- American Medical Association, the number of visits to alterna-
toms of cognitive confusion, emotional instability and memo- tive practitioners exceeds visits to traditional medical doctors;
ry loss. Within an hour it was determined that she was de- the amount of money spent on herbal medicines and nutrition
pressed. I didnt buy it. My mom was acting strangely, not de- therapy accounts for more than half of all out-of-pocket ex-
pressed. I requested a second opinion from a neurologist. penses to physicians; and, most disturbingly, 60 percent of pa-
A CT scan revealed an orange-size meningioma tumor. Af- tients who undergo alternative treatments do not report that in-
ter its removal, my mom was formation to their physician a serious, and even potentially fa-
There is only back to her bright and cheery tal, problem if herbs and medicines are inappropriately mixed.
scientific medicine self such a remarkably recu- For example, the September 17 issue of the Journal of the
that has been perative and pliable organ is American Medical Association reported the results of a study on
the brain. Unfortunately, with- St. Johns wort. The herb, derived from a blooming Hypericum
tested and in a year my mom had two perforatum plant and hugely popular as an alternative elixir (to
alternative new tumors in her brain. the tune of millions of dollars annually), can significantly impair
medicine that has Three more rounds of this cy- the effectiveness of dozens of medications, including those used
not been tested. cle of surgical removal and tu- to treat high blood pressure, cardiac arrhythmias, high choles-
mor return, plus two doses of terol, cancer, pain and depression. The studys authors show
gamma knife radiation (pinpoint-accurate beams that destroy that St. Johns wort affects the liver enzyme cytochrome P450
cancer cells), finally led to the dreaded prognosis: there was 3A4, essential to metabolizing at least half of all prescription
nothing more to be done. drugs, thereby speeding up the breakdown process and short-
What is a skeptic to do? An ideological commitment to sci- changing patients of their lifesaving medications.
ence is one thing, but this was my mom! I turned to the literature, But there is a deeper problem with the use of alternatives
and with the help of our brilliant and humane oncologist, Avrum whose benefits have not been proved. All of us are limited to a
Bluming, determined that my mom should try an experimental few score years in which to enjoy meaningful life and love. Time
treatment, mifepristone, a synthetic antiprogestin better known is precious and fleeting. Given the choice of spending the next
as RU-486, the morning after contraception drug. A small- couple months schlepping my mother around the country on a
sample study suggested that it might retard the growth of tumors. wild goose chase versus spending the time together, my dad and
It didnt work for my mom. She was dying. There was nothing I decided on the latter. She died a few months later, on Septem-
to lose in trying alternative cancer treatments, right? Wrong. ber 2, 2000, three years ago to the day I penned this column.
The choice is not between scientific medicine that doesnt Medicine is miraculous, but in the end, life ultimately turns
work and alternative medicine that might work. Instead there is on the love of the people who matter most. It is for those rela-
only scientific medicine that has been tested and everything else tionships, especially, that we should apply the ancient medical
(alternative or complementary medicine) that has not been principle Primum non nocere first, do no harm.
tested. A few reliable authorities test and review the evidence for
BRAD HINES
some of the claims notably Stephen Barretts Quackwatch Michael Shermer is publisher of Skeptic (www.skeptic.com)
(www.quackwatch.org), William Jarviss National Council and author of How We Believe and In Darwins Shadow.
The life of Judah Folkman took an unexpected turn one you have very few, if any, adverse effects on the organism.
morning in May 1998. That day, a front-page article in Targeting endothelial cells has some advantages: these
the New York Times announced that Folkman, a profes- cells are genetically stable, meaning that they do not
sor at the Harvard Medical School in Boston, had discov- mutate. In contrast, tumor cells tend to mutate and in this
ered two natural compounds, angiostatin and endostatin, way they often become drug-resistant. Therefore, devel-
that dramatically shrunk tumors in mice by cutting the opment of acquired drug resistance, which is common
cancers blood supply. Along the story was a quote from with chemotherapy, is less likely with angiogenesis
Nobel laureate James Watson: "Judah is going to cure inhibitors. Moreover, each endothelial cell can support up
cancer in two years." Watson eventually backed off, but to 100 tumor cells; that means that by knocking out just
the media frenzy had already exploded worldwide, trans- few endothelial cells you have an effect on hundreds of
forming Folkman into a reluctant hero in the fight against tumor cells.
cancer.
Folkman's reputation in the medical world was well What impact did the sudden celebrity have on your daily
established long before he hit the headlines. The son of a work?
rabbi, he was a student when he developed the first At the beginning I felt an enormous pressure. Patients
implantable atrio-ventricular pacemaker in the 1950s. were calling at all times and many flew to Boston. We
Later, he pioneered the first implantable polymers to hired three people just to answer the patients' and media's
obtain slow drug releasing. At the age of 34, when he queries around the clock. [The news] raised expectations
became the youngest professor of surgery to be hired at and demand for angiogenesis inhibitors before these drugs
the Harvard Medical School, he was already studying had completed testing in clinical trials. On the other hand,
ways to block the formation of new blood vessels--a there are many patients alive today because they were
process called angiogenesis--to stop tumor growth. His treated with antiangiogenic drugs: thalidomide for multi-
ideas, initially met with skepticism by oncologists, are ple myeloma or low-dose interferon alpha for giant cell
today the basis for an area of research that is attracting bone tumors or for angioblastomas. For any new type of
enormous interest. At least 20 compounds with an effect therapy, there is always a dilemma about when to inform
on angiogenesis are now being tested in humans for a the public. If its too early, then physicians are besieged by
range of pathologies that include cancer, heart disease and calls from patients for drugs that cannot be obtained. If
vision loss. But the premature hype continues to generate too late, then critics say that hope was destroyed for
disproportioned hopes among the press, the public and patients with advanced disease. Our own research work
the stock market. Recently, we met Folkman in his labo- was temporarily impacted because of many phone calls,
ratory at the Childrens Hospital in Boston to ask about but in the long run the effect was minimal.
his work and the progress of clinical trials on endostatin
and angiostatin.Sergio Pistoi and Chiara Palmerini The first tests in humans with endostatin began two
years ago. What are the results so far?
What makes anti-angiogenesis drugs a promising strat- The rules of clinical trials for endostatin are the same
that the FDA sets for any other cancer drug. In the phase
egy in cancer therapies? one of the trial you are only allowed to start with very few
Many experiments showed that tumor growth and patients, for which any other option has failed, slowly
metastasis are angiogenesis-dependent. Tumors cannot increasing the dose in order to test the drugs safety. All
grow unless they recruit their own private blood supply. phase I studied have shown that both endostatin and
That is why microvascular endothelial cells [the cells lin- angiostatin are very well tolerated and have virtually no
ing capillaries], which are essential for new blood vessel side effects. This is the most exciting thing about these
growth, have become an important target in cancer thera- drugs. On average a patient cannot stay on chemotherapy
py. Antiangiogenic compounds do not attack the tumor for more than six weeks, because either there are too
cells directly, as chemotherapies do. Instead they turn many side effects or the tumor escapes [becomes resistant
endothelial cells off, so they wont make new blood ves- to the treatment]. So far, no patient has been reported to
sels, and the tumor will eventually stop growing. The [have to] stop endostatin because of adverse reactions.
effect of angiostatin and endostatin is tumor-specific. So
Still, these results are very far from the dramatic Do you think that clinical trials for antiangiogenic drugs
improvements that you observed in mice. Why is it so should follow different rules?
difficult to replicate the experiments in humans? No. The current guidelines for clinical trials are based on
Well, first of all these [Phase I] experiments are primari- determining safety and efficacy and are working well.
ly designed to test a drugs safety, not its efficacy. Then, However, we must not forget the differences between anti-
when you experiment with mice you can increase the angiogenic therapy and conventional chemotherapy. Some
dose, give different drugs in combination, and choose on definitions, for example, do not have the same value. One
which tumors and at what stage you want to try them. example is the term "stable disease." For conventional
With humans, of course, the rules are strict: you can only chemotherapy it usually means "failure," because it may
give a single drug to patients with very advanced tumors, not last long and may be accompanied by many side
starting at very low doses. For example, we found the effects and a poor quality of life. In contrast, for anti-
most dramatic effects in mice when endostatin and angio- angiogenic therapy, patients with stable disease have vir-
statin were used in combination, but the FDA will not tually no symptoms and there is less of a risk of drug
allow to use both drugs together before the end of phase resistance if they are treated for a long time. Some patients
II, maybe early phase III [large-scale, with many human refer to this situation as "having cancer without disease."
patients] of the trials. Moreover, we have evidence that the In this case, the term "stable disease" has a completely dif-
drugs would work better if given at an early stage of the ferent meaning.
tumor. Another complication is that each tumor puts out
different amounts of angiogenic stimulators. Some breast Are you involved in the clinical trials of endostatin and
cancers, for instance, make only one angiogenic factor angiostatin?
while others make six. That means that you have to bal- Trials are being carried on at centers in Boston; Houston,
ance the dose against a specific tumor, as much as you Tex.; Madison, Wis.; and Amsterdam and Utrecht in the
would adjust the dose of insulin according to your blood Netherlands under the supervision of experienced oncolo-
sugar levels for diabetes. But this is not the way you do gists. I have not participated directly. However, our labo-
clinical trials. You cant start with the dose you think is ratory has helped to develop some of the blood tests that
effective for each patient: everyone has to stay on a fixed are being evaluated in these trials and I help oncologists to
schedule. But we are beginning to learn that when the design the trials.
drugs are approved--I dont know how many years that
will be--a physician wont just stay on the same dose no What are your expectations for the future of these
more than you do with penicillin. drugs?
My vision is that without any major side effect or resist-
After endostatin and angiostatin were first hailed as the
ance these drugs could be used in combination with other
miracle cure, now many say that they are not meeting drugs or radiation therapy virtually lifelong. For the long
the expectations. How do you feel about all the ups and term, over the next five to 10 years, we can ask whether
downs of your work in the press? the risk of drug resistance and the harsh side effects of
I feel that these drugs are not much different than any treating cancer can be reduced, and whether cancer can
drugs going through clinical trials. Expectations are not ever be converted to a chronic manageable disease like
the same for everyone. For example, researchers may have diabetes or heart disease.
different expectation than the public or the press. Suppose
that you read the abstract of phase I endostatin trial say- Sergio Pistoi is a freelance science reporter based in
ing that the drug has shown "linear pharmacokinetics." It Arezzo, Italy. He can be found at www.greedybrain.com
is a very good finding for an early trial, because it means
that blood levels of the drug directly correlated with Chiara Palmerini is a staff science writer for the Italian
increasing doses, as predicted. But the same report can be weekly magazine Panorama.
SENAGO, ITALY Three centuries ago cardinals seeking Between them sits Peter H. Duesberg, an American
refuge from a plague in nearby Milan stayed here at the virologist who has also challenged that belief. Duesberg
Villa San Carlo Borromeo, a grand estate surveying is now tilting at a different windmill, however. In a
the village from its highest hill. The villa and its inhab- reedy voice clipped by a German accent, he explains
itants have fallen on harder times since. The cracked why he believes the scientific establishment has spent
plaster and faded paint on its high walls are covered two decades perfecting an utterly incorrect theory of
with modern art of dubious quality. Now it is the pri- how cancer arises.
vate museum of Armando Verdiglione, a once promi- It is an odd speaking engagement for a scientist who
nent psychoanalyst whose reputation was stained isolated the first cancer-causing gene from a virus at age
when he was convicted in 1986 of swindling wealthy 33, earned tenure at the University of California at
patients. Today the villa is hosting refugees of a differ- Berkeley at 36 and was invited into the exclusive Na-
ent sort: scientific dissidents flown in by Verdiglione tional Academy of Sciences at 49. Today many of his
from around the world to address an eclectic confer- colleagues from those early efforts to map the genetic
ence of 100-odd listeners. structure of retroviruses occupy the top of the field.
At the other end of the dais from Verdiglione is Sam Robert A. Weinberg has a huge lab at the Whitehead In-
Mhlongo, a former guerrilla fighter and prison-mate of stitute for Biology in Cambridge, Mass., with 20 re-
Nelson Mandela and now head of the department of search assistants, a multimillion-dollar budget and a
family medicine and primary health care at the Med- National Medal of Science to hang in his office. David
ical University of Southern Africa near Pretoria. Mhlon- Baltimore got a Nobel Prize and now presides over the
go has urged President Thabo Mbeki to question the California Institute of Technology.
near universal belief that AIDS is epidemic in South I could have played the game and basked in the
Africa and that HIV is its cause. glory of early success, Duesberg says, and he is prob-
ably right. But instead he broke ranks and bruised egos.
PETER H. DUESBERG: SHUNNED SCIENTIST And so, 10 days before attending this eccentric sympo-
sium, Duesberg had to dash off a desperate letter to
His theory that HIV does not cause AIDS, outlined at duesberg.com, Abraham Katz, one of the handful of rich philan-
is rebutted at www.niaid.nih.gov/spotlight/hiv00/ thropists who have been his sole source of funding since
Twice married, he has one five-year-old son and three grown daughters. he was cut off from all the normal channels five years
When not in the lab, he likes to roller-skate. ago.
Surely 5 percent of the funds for science could be set aside for work on Were down to our last $45,000, the 64-year-old
fringe theories that could be revolutionary. Duesberg confides glumly as we stand in the dark court-
malignancy often contain different mutations, and no clear pat- ploidy creates massive genetic chaos inside the cell. The cell be-
tern perfectly matches the supposed cause to actual human dis- comes essentially a whole new species unto itself, Duesberg says.
ease. Cells taken from patients tumors typically translate their Any new species of cell is extremely unlikely to do better in the
mutant genes into a mere trickle of protein, in contrast to the body than a native human cell and that may explain why tu-
flood of mutated protein churning in cells transformed by a virus. mors take so long to develop even after intense exposure to a car-
Beginning with his 1983 paper, Duesberg has also picked cinogen, he argues. The aneuploid cells must go through many
at theoretical weak spots in the orthodox view. Some tumors are divisions, evolving at each one, before they hit on a combination
caused by asbestos and other carcinogens that are chemically in- that can grow more or less uncontrollably anywhere in the body.
capable of mutating specific genes, he points out. Mice geneti- So far Duesberg has only a scattering of experimental evi-
cally engineered to lack tumor suppressor genes and to overex- dence to support his hypothesis. In 1998 he showed that there